<DOC>
	<DOCNO>NCT02069899</DOCNO>
	<brief_summary>International , multicenter , long-term , follow-up study enroll HLH patient receive NI-0501 previous clinical trial , context clinical development program NI-0501</brief_summary>
	<brief_title>Long-term Follow-up HLH Patients Who Received Treatment With NI-0501 , Anti-interferon Gamma Monoclonal Antibody</brief_title>
	<detailed_description>The aim study monitor long-term safety profile patient previously receive least one dose NI-0501 , include survival several time point administration NI-0501 . Moreover study elimination profile NI-0501 assess immunogenicity NI-0501 . Furthermore event patient , upon request treat physician , maintain NI-0501 treatment beyond foreseen 8 week , NI-0501 safety , tolerability , efficacy PK profile closely monitored patient treatment discontinuation .</detailed_description>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Having receive least one dose NI0501 . Having sign Informed Consent patient patient 's legal representative ( ) , applicable , assent patient legally capable providing .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemophagocytic lymphohistiocytosis ( HLH ) previously treat NI-0501</keyword>
</DOC>